Overall survival (os) of patients (pts) with relapsed and refractory multiple myeloma (rrmm): Adjusting for crossover in the mm-003 trial for pomalidomide plus low-dose dexamethasone (pom + lodex) vs. High-dose dexamethasone (hidex)

Publication Type:
Poster


Citation:

Morgan G, San Miguel J, Dhanasiri S, Lee D, Palumbo A, Facon T, Zaki M, Yu X, Sternas L, Jacques C, Weisel K, Offner F and Dimopoulos M. Overall survival (os) of patients (pts) with relapsed and refractory multiple myeloma (rrmm): Adjusting for crossover in the mm-003 trial for pomalidomide plus low-dose dexamethasone (pom + lodex) vs. High-dose dexamethasone (hidex) 19th Congress of European Hematology Association. Milan, Italy. 12-15 June 2014. Poster.

 


Link to publication ⟶

⟵ Back to Search Results